Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Methods of Documentation VI: Case Management Model01:15

Methods of Documentation VI: Case Management Model

The case management model is a multidisciplinary approach that involves healthcare professionals from diverse disciplines, such as physicians, nurses, therapists, social workers, and pharmacists, working collaboratively to address the various needs of patients. Each healthcare professional brings unique expertise and perspectives, contributing to a more comprehensive understanding of the patient's condition and tailoring treatment plans accordingly.
For example, a patient with a chronic illness...
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
Methods of Medium Optimization01:28

Methods of Medium Optimization

Optimizing growth media enhances microbial proliferation and maximizes product yield. Statistical experimental design methodologies provide structured and reproducible approaches, offering progressively higher levels of robustness and efficiency.The One-Factor-at-a-Time (OFAT) MethodThe One-Factor-at-a-Time (OFAT) method involves adjusting a single variable while keeping all others constant. However, it cannot detect interactions between variables, often leading to suboptimal outcomes when...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost-Effectiveness of Universal Newborn Screening and Disease-Modifying Therapies for Spinal Muscular Atrophy in Taiwan.

Value in health regional issues·2026
Same author

Machine learning-based integration of respiratory oscillometry and spirometry for predicting clinical outcomes in spinal muscular atrophy.

European journal of pediatrics·2026
Same author

Thrombosis in Neuromuscular Medicine: Current Evidence, Unmet Needs, and Future Directions.

Journal of clinical medicine·2026
Same author

Bacterial cytochrome P450 for oxidative halogenated biaryl coupling.

ACS catalysis·2026
Same author

Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial.

Nature medicine·2025
Same author

MTID-TS: Multimodal Training with Incomplete Data using Teacher-Student-Based Strategy on Medical Domain.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2025

Related Experiment Video

Updated: Jun 17, 2026

Direct Microbial Identification using An Automated Microbial Identification System to Facilitate the EUCAST RAST Method Without Mass Spectrometry
09:07

Direct Microbial Identification using An Automated Microbial Identification System to Facilitate the EUCAST RAST Method Without Mass Spectrometry

Published on: May 24, 2024

Optimizing DMD management in Asia: Current challenges and future directions.

Wen-Chin Weng1,2,3, Sophelia H S Chan4, Roy Gomez5

  • 1Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.

Journal of Neuromuscular Diseases
|February 20, 2025
PubMed
Summary

Duchenne muscular dystrophy (DMD) management in Asia shows significant variation, with cost impacting treatment decisions. A centralized patient registry is proposed to improve care standards and gather essential data for Duchenne muscular dystrophy patients.

Keywords:
AsiaDMDDuchenne muscular dystrophygene therapypatient registrysteroid therapy

Related Experiment Videos

Last Updated: Jun 17, 2026

Direct Microbial Identification using An Automated Microbial Identification System to Facilitate the EUCAST RAST Method Without Mass Spectrometry
09:07

Direct Microbial Identification using An Automated Microbial Identification System to Facilitate the EUCAST RAST Method Without Mass Spectrometry

Published on: May 24, 2024

Area of Science:

  • Neurology
  • Genetics
  • Public Health

Background:

  • Duchenne muscular dystrophy (DMD) management has advanced since 1970, improving life expectancy, yet it remains a fatal condition.
  • Current challenges in DMD care persist despite therapeutic progress.

Purpose of the Study:

  • To assess current Duchenne muscular dystrophy (DMD) management standards and practices across Asia.
  • To identify inconsistencies, unmet needs, and future directions in regional DMD patient care.

Main Methods:

  • Convened clinical experts from Hong Kong, Singapore, and Taiwan in September 2023.
  • Conducted a pre-meeting survey to gauge professional perspectives on Duchenne muscular dystrophy (DMD) diagnosis, assessment, and treatment.

Main Results:

  • Genetic profiling is a universally adopted diagnostic standard for Duchenne muscular dystrophy (DMD).
  • Steroid therapy is central to DMD care, but timing and continuation post-ambulation loss are debated.
  • Gene therapy offers promise but faces barriers including cost, adverse events, and patient selection; a centralized Duchenne muscular dystrophy (DMD) registry is strongly supported for data collection and trial facilitation.

Conclusions:

  • Duchenne muscular dystrophy (DMD) care in Asia exhibits considerable heterogeneity, significantly influenced by financial and reimbursement factors.
  • A centralized patient registry is identified as a key resource to address these disparities and inform Duchenne muscular dystrophy (DMD) management and policy.